Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03691831
Other study ID # A-101-WART-302
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 13, 2018
Est. completion date July 9, 2019

Study information

Verified date October 2020
Source Aclaris Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase 3 Study of A-101 Topical Solution in Subjects with Common Warts


Description:

A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts


Recruitment information / eligibility

Status Completed
Enrollment 502
Est. completion date July 9, 2019
Est. primary completion date April 21, 2019
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria: 1. Subject or legal guardian is able to comprehend and is willing to sign an informed consent/assent for participation in this study. 2. Male or female = 2 years old. 3. Subject has a clinical diagnosis of common warts (verruca vulgaris). 4. Subject has at least 1 and up to 6 clearly identifiable common warts located on the trunk or extremities that meet the requirements as defined below: 1. Have a longest axis that is =3 and =8 mm and have a thickness of =3mm 2. Be a discrete lesion, i.e. each wart meeting the entry criteria is clearly separated from other warts. 3. Be present for at least 4 weeks 4. Not be covered with hair which, in the investigator's opinion, would interfere with the study medication treatment or the study evaluations 5. Not be in an intertriginous fold 6. Periungual, subungual, genital, anal, mosaic, plantar, flat and filiform warts are excluded from treatment and evaluation. If a subject has these types of warts, but also has warts that meet the inclusion criteria, the subject will NOT be excluded from the study. 5. Each common wart identified for treatment must have a PWA = 2. 6. Subject's chemistry and complete blood count results are within normal limits. If any of the laboratory values are outside normal range, the treating investigator must assess the value(s) as NOT clinically significant and document this in the subject's medical chart in order for the subject to be eligible for randomization. 7. Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair the evaluation of the identified common warts or which exposes the subject to an unacceptable risk by study participation. 8. Subject is willing and able to follow all study instructions and to attend all study visits. 9. Subject must be the only individual in a household participating in the study. Exclusion Criteria: 1. Subject has clinically atypical common warts. 2. Subject is immunocompromised (e.g., due to chemotherapy, systemic steroids, genetic immunodeficiency, transplant status, etc.). 3. Subject has a history of Human Immunodeficiency Virus (HIV) infection. 4. Subject has had any Human Papilloma Virus (HPV) vaccine within 6 months prior to Visit 1. 5. Subject has used any of the following intralesional therapies within the specified period prior to Visit 2: 1. Immunotherapy (e.g., Candida antigen, mumps antigen, Trichophyton antigen); 8 weeks 2. Anti-metabolite therapy (e.g., bleomycin, 5-fluorouracil); 8 weeks 6. Subject has used any of the following systemic therapies within the specified period prior to Visit 2: 1. Immunomodulatory/immunosuppressant therapy (e.g., etanercept, alefacept, infliximab); 16 weeks 2. Glucocorticosteroids (inhaled and intra-nasal steroids are permitted); 28 days 7. Subject has used any of the following topical therapies within the specified period prior to Visit 2 on, or in the proximity to any of the common warts identified for treatment, that in the investigator's opinion interferes with the study medication treatment or the study assessments: 1. LASER, light or other energy-based therapy (e.g., intense pulsed light [IPL], photodynamic therapy [PDT]); 180 days 2. Immunotherapy (e.g., imiquimod, squaric acid dibutyl ester[SADBE], etc.) 12 weeks 3. Liquid nitrogen, electrodesiccation, curettage; 60 days 4. Hydrogen peroxide; 90 days 5. Antimetabolite therapy (e.g., 5-fluorouracil); 8 weeks 6. Retinoids; 90 days 7. Over-the-counter (OTC) wart therapies and cantharidin; 28 days 8. Subject currently has or has had any of the following within the specified period prior to Visit 1 on or in the proximity to any of the common warts identified for treatment that, in the investigator's opinion, interferes with the study medication treatment or the study assessments: 1. Cutaneous malignancy; 180 days 2. Sunburn; currently 3. Pre-malignancy (e.g., actinic keratosis); currently 9. Subject has a history of sensitivity to any of the ingredients in the study medications. 10. Subject has any current skin or systemic disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations. 11. Participation in another therapeutic investigational drug/device trial in which administration of an investigational treatment occurred with 30 days prior to Visit 1. 12. Subject has an active malignancy. 13. Subjects is viewed by the Principal Investigator as not being able to complete the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Active
A-101 45% (hydrogen peroxide 45% topical solution)
Other:
Vehicle
Vehicle solution containing isopropyl alcohol and water

Locations

Country Name City State
United States Aclaris Investigational Site Anderson South Carolina
United States Aclaris Investigational Site Arlington Texas
United States Aclaris Investigational Site Beachwood Ohio
United States Aclaris Investigational Site College Station Texas
United States Aclaris Investigational Site Coral Gables Florida
United States Aclaris Investigational Site Denver Colorado
United States Aclaris Investigational Site Encinitas California
United States Aclaris Investigational Site Fort Smith Arkansas
United States Aclaris Investigational Site Glendale Arizona
United States Aclaris Investigational Site Houston Texas
United States Aclaris Investigational Site Knoxville Tennessee
United States Aclaris Investigational Site Lynchburg Virginia
United States Aclaris Investigational Site Miami Florida
United States Aclaris Investigational Site Nashville Tennessee
United States Aclaris Investigational Site New Albany Indiana
United States Aclaris Investigational Site Norfolk Virginia
United States Aclaris Investigational Site Omaha Nebraska
United States Aclaris Investigational Site Quincy Massachusetts
United States Aclaris Investigational Site Raleigh North Carolina
United States Aclaris Investigational Site Rochester New York
United States Aclaris Investigational Site Rockville Maryland
United States Aclaris Investigational Site Saint Joseph Missouri
United States Aclaris Investigational Site San Diego California
United States Aclaris Investigational Site Upper Saint Clair Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Aclaris Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60) The primary efficacy endpoint is the number of subjects whose identified common warts are determined to be clear on the Physician Wart Assessment (PWA) scale (PWA=0) at Visit 10 (Day 60).
Efficacy will be assessed using the Physician's Wart Assessment Scale (PWA) which is a 4 point scale. A higher amount of warts cleared represents a better outcome.
Day 60
Secondary Number of Subjects With Complete Clearance of All Treated Common Warts Between Active and Vehicle on the Physician Wart Assessment (PWA) Scale (PWA=0) at Visit 13 (Day 137) Number of subjects whose identified common warts are determined to be clear on the Physician Wart Assessment (PWA) scale (PWA=0) at Visit 13 (Day 137).
Efficacy will be assessed using the Physician's Wart Assessment Scale (PWA) which is a 4 point scale. A higher amount of warts cleared represents a better outcome.
Day 137
Secondary Mean Per-Subject Percent of All Warts That Were Clear on the Physician Wart Assessment (PWA) Scale Between Active and Vehicle That Are Clear (PWA=0) at Visit 13 (Day 137) Mean Per-Subject Percent of all Warts that were Clear on the Physician Wart Assessment (PWA) scale between Active (A-101 45%) and Vehicle that are clear (PWA=0) at Day 137.
Clearance of all treated warts will be assessed using the Physician Wart Assessment (PWA) scale which is a four point scale. A higher amount of warts cleared represents a better outcome.
Day 137
Secondary Number of Subjects With a Single Wart at Baseline Whose Wart Was Clear on the PWA Scale Between Active and Vehicle Group (PWA=0) at Visit 10 (Day 60) Comparison between Active (A-101 45%) and Vehicle of subjects with a single wart at baseline, whose wart is clear (PWA=0) at Day 60.
Clearance of the single wart at baseline will be assessed using the Physician Wart Assessment (PWA) scale which is a four point scale. A higher amount of warts cleared represents a better outcome.
Day 60
Secondary Median Time for Subjects to Achieve Clearance (PWA=0) of All Treated Common Warts Comparison between Active (A-101 45%) and Vehicle with respect to the median time to achieve onset of clearance (PWA=0) for all treated warts at Day 137.
Clearance of all treated warts will be assessed using the Physician Wart Assessment (PWA) scale which is a four point scale. A higher amount of warts cleared represents a better outcome.
Day 137
See also
  Status Clinical Trial Phase
Suspended NCT01796795 - Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients Phase 2
Completed NCT03687372 - Study of A-101 Topical Solution for the Treatment of Common Warts Phase 3
Completed NCT00328991 - Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts N/A
Completed NCT05115669 - Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts N/A
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Not yet recruiting NCT04288817 - Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts Phase 3
Active, not recruiting NCT05896215 - OM202JP Clinical Study of KNP2002 Phase 2
Completed NCT03278028 - A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts Phase 2
Completed NCT03812510 - Safety Study of A-101 Topical Solution for the Treatment of Common Warts Phase 3
Recruiting NCT05799157 - Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts Phase 2
Recruiting NCT06214559 - Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts. N/A
Recruiting NCT03977753 - Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts Phase 4
Completed NCT03210337 - A Phase2 of A-101 Topical Solution in Subjects With Common Warts Phase 2
Completed NCT03183765 - Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Phase 4